These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38290021)

  • 1. OTOTOXICITY OF ANTIMYCOBACTERIAL THERAPY: MANIFESTATIONS, MECHANISMS OF MANAGEMENT AND CONTROL.
    Makoyda I; Ostrovskyy М; Shevchuk-Budz U; Molodovets О; Zuban A
    Wiad Lek; 2023; 76(12):2587-2592. PubMed ID: 38290021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
    Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
    Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis.
    Tabriz NS; Skak K; Kassayeva LT; Omarkulov BK; Grigolashvili MA
    Microb Drug Resist; 2020 Aug; 26(8):997-1004. PubMed ID: 32181685
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
    Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
    Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa.
    Rabna P; Ramos J; Ponce G; Sanca L; Mané M; Armada A; Machado D; Vieira F; Gomes VF; Martins E; Colombatti R; Riccardi F; Perdigão J; Sotero J; Portugal I; Couto I; Atouguia J; Rodrigues A; Viveiros M
    PLoS One; 2015; 10(5):e0127536. PubMed ID: 26017968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANALYSIS OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS FOR DRUG-RESISTANT TUBERCULOSIS IN PRYKARPATTIA. CHALLENGES OF OUR TIME.
    Makoyda I; Ostrovskyy М; Ostrovska K; Todoriko L; Babliuk L; Vepryk T; Melnyk-Sheremeta O
    Wiad Lek; 2022; 75(1):112-116. PubMed ID: 35092258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
    Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
    Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TB or not TB? Definitive determination of species within the Mycobacterium tuberculosis complex in unprocessed sputum from adults with presumed multidrug-resistant tuberculosis.
    Mbelele PM; Sauli E; Mpolya EA; Mohamed SY; Addo KK; Mfinanga SG; Heysell SK; Mpagama S
    Trop Med Int Health; 2021 Sep; 26(9):1057-1067. PubMed ID: 34107112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of an Xpert-based diagnostic algorithm for the rapid detection of drug-resistant tuberculosis among high-risk populations in a low-incidence setting.
    Chiang TY; Fan SY; Jou R
    PLoS One; 2018; 13(7):e0200755. PubMed ID: 30011319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance pattern and mutation pattern in pediatric tuberculosis: Study from north India.
    Khurana P; Saigal K; Ghosh A
    Indian J Tuberc; 2021 Oct; 68(4):481-484. PubMed ID: 34752317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
    Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
    [No Abstract]   [Full Text] [Related]  

  • 18. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Souleymane MB; Piubello A; Lawan IM; Hassane-Harouna S; Assao-Neino MM; Soumana A; Hamidou-Harouna Z; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Schwoebel V; Mamadou S; Lynen L; De Jong B; Van Deun A; Decroo T
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32703777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.